Takehara T, et al. - Researchers tested the safety and effectiveness of sofosbuvir–velpatasvir with or without ribavirin for 12 weeks in patients with any hepatitis C virus (HCV) genotype and decompensated cirrhosis (Child–Pugh–Turcotte [CPT] class B or C) in Japan. In this phase 3 study, patients were randomized 1:1 to receive sofosbuvir–velpatasvir with or without ribavirin for 12 weeks. They found that for Japanese patients with HCV and decompensated cirrhosis, sofosbuvir–velpatasvir for 12 weeks was highly efficacious and well-tolerated. It was noted that ribavirin increased toxicity but did not improve effectiveness. Regardless of genotype or CPT class, the sustained virologic response 12 weeks post treatment rate was high.